Sources

Last updated: August 25, 2026

1. Echelibe et al., ITAM optimization platform, manuscript under revision, 2026.
2. Xu X, Sun Q, Liang X, et al. Mechanisms of Relapse After CD19 CAR T-Cell Therapy for Acute Lymphoblastic Leukemia and Its Prevention and Treatment Strategies. Front Immunol. 2019;10:2664. doi:10.3389/fimmu.2019.02664
3. Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N Engl J Med. 2018;378(5):439–448. doi:10.1056/NEJMoa1709866
4. Hou B, Tang Y, Li W, Zeng Q, Chang D. Efficiency of CAR-T Therapy for Treatment of Solid Tumor in Clinical Trials: A Meta-Analysis. Dis Markers. 2019;2019:3425291. doi:10.1155/2019/3425291
5. An N, Wang D, Zhang P, et al. In vivo generation of anti-BCMA CAR-T cells in relapsed or refractory multiple myeloma: a phase 1 study. Nat Med. 2026;32(4):1257–1266. doi:10.1038/s41591-026-04244-6